Amazon Web Services (AWS) has introduced Amazon Bio Discovery, an artificial intelligence application aimed at significantly speeding up early-stage drug discovery. The tool enables scientists to conduct complex computational workflows without the need for coding.
The platform provides researchers with access to a specialized library of biological foundation models for generating and evaluating potential drug molecules. An integrated AI agent assists users in selecting models, setting parameters, and interpreting results. Shortlisted candidates can be sent to partner labs for synthesis and testing, with outcomes feeding back into the system for iterative design.
AWS stated that this new tool can drastically reduce the time to create hundreds of potential drug candidates from months to just a couple of weeks. Early adopters include Bayer, the Broad Institute, and Voyager Therapeutics.
In a notable collaboration, the platform generated nearly 300,000 novel antibody molecules, narrowing them down to 100,000 candidates for lab testing in a compressed timeframe. AWS emphasized that the service is designed to augment, not replace, scientific expertise.
AWS will also introduce a separate AI platform with Boston Consulting Group and Merck to improve clinical trial site selection.